Clinical Trial: Lipoic Acid as a Treatment for Acute Optic Neuritis
Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study
Brief Summary: The purpose of this study is to determine if oral lipoic acid can safely help relieve permanent optic nerve injury in patients diagnosed with acute optic neuritis. It will also explore how the body absorbs and breaks down the study drug, and what effects it has on the immune system.
Detailed Summary:
Oral lipoic acid is an antioxidant that helps proteins work in the body. It is available in oral and intravenous formulations and has been used in the past to treat nerve damage like that seen in diabetes and some other metabolic disorders. It is available as a dietary supplement in the United States.
Patients with a diagnosis of acute optic neuritis who are enrolled in the study will undergo medical and nervous system examinations, and blood draws. The study doctor will take a medical history and perform physical examinations. Research assistants at the MS Center, who are trained in blood draws, will perform the blood draws. Patients will also undergo Optical coherence tomography (OCT) examination at Casey Eye Institute, and receive two MRIs at Oregon Health and Science University (OHSU). Because it is a placebo-controlled trial, subjects will have a 50:50 chance of receiving either placebo (inactive) or study drug. If enrolled in the study, patients will take two gel capsules of the study drug or placebo at the same time every day for six weeks.
Sponsor: Oregon Health and Science University
Current Primary Outcome: The primary outcome measure will be the difference from baseline in retinal nerve fiber layer (RNFL) thickness of the affected optic nerve, as determined by OCT, at 12 and 24weeks post LA treatment. [ Time Frame: Baseline, Week 24 ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Secondary outcome measures to assess optic nerve injury will be changes from baseline in the RNFL thickness at week 24, and changes from baseline in low- and high-contrast visual acuity, contrast sensitivity, and visual field changes at weeks 12 and 24. [ Time Frame: Baseline, Week 24 ]
Original Secondary Outcome: Same as current
Information By: Oregon Health and Science University
Dates:
Date Received: August 10, 2010
Date Started: January 2011
Date Completion: October 2015
Last Updated: February 2, 2015
Last Verified: February 2015